

# Firdos Ahmad

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/732273/firdos-ahmad-publications-by-citations.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

44  
papers

841  
citations

14  
h-index

28  
g-index

61  
ext. papers

1,100  
ext. citations

7.8  
avg, IF

4.07  
L-index

#	Paper	IF	Citations
44	The GSK-3 family as therapeutic target for myocardial diseases. <i>Circulation Research</i> , <b>2015</b> , 116, 138-49	15.7	127
43	Cardiac fibroblast glycogen synthase kinase-3 $\beta$ regulates ventricular remodeling and dysfunction in ischemic heart. <i>Circulation</i> , <b>2014</b> , 130, 419-30	16.7	111
42	GSK-3 $\beta$ is a central regulator of age-related pathologies in mice. <i>Journal of Clinical Investigation</i> , <b>2013</b> , 123, 1821-32	15.9	108
41	Loss of Adult Cardiac Myocyte GSK-3 Leads to Mitotic Catastrophe Resulting in Fatal Dilated Cardiomyopathy. <i>Circulation Research</i> , <b>2016</b> , 118, 1208-22	15.7	55
40	Glycogen synthase kinase-3 $\beta$ limits ischemic injury, cardiac rupture, post-myocardial infarction remodeling and death. <i>Circulation</i> , <b>2012</b> , 125, 65-75	16.7	48
39	Cardiomyocyte-specific deletion of Gsk3 $\beta$ mitigates post-myocardial infarction remodeling, contractile dysfunction, and heart failure. <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 64, 696-708	15.1	42
38	Molecular defects in ITGA2B and ITGB3 genes in patients with Glanzmann thrombasthenia. <i>Journal of Thrombosis and Haemostasis</i> , <b>2009</b> , 7, 1878-85	15.4	41
37	Relative contributions of stromal interaction molecule 1 and CalDAG-GEFI to calcium-dependent platelet activation and thrombosis. <i>Journal of Thrombosis and Haemostasis</i> , <b>2011</b> , 9, 2077-86	15.4	36
36	Platelet activation markers in evaluation of thrombotic risk factors in various clinical settings. <i>Blood Reviews</i> , <b>2019</b> , 37, 100583	11.1	31
35	Characterisation of mutations and molecular studies of type 2 von Willebrand disease. <i>Thrombosis and Haemostasis</i> , <b>2013</b> , 109, 39-46	7	25
34	Human genome-wide association and mouse knockout approaches identify platelet supervillin as an inhibitor of thrombus formation under shear stress. <i>Circulation</i> , <b>2012</b> , 125, 2762-71	16.7	21
33	Inherited platelet function disorders versus other inherited bleeding disorders: an Indian overview. <i>Thrombosis Research</i> , <b>2008</b> , 121, 835-41	8.2	20
32	Troponin I-interacting protein kinase: a novel cardiac-specific kinase, emerging as a molecular target for the treatment of cardiac disease. <i>Circulation Journal</i> , <b>2014</b> , 78, 1514-9	2.9	14
31	Emerging roles of GSK-3 $\beta$ in pathophysiology: Emphasis on cardio-metabolic disorders. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , <b>2020</b> , 1867, 118616	4.9	14
30	Cardiomyocyte-GSK-3 $\beta$ promotes mPTP opening and heart failure in mice with chronic pressure overload. <i>Journal of Molecular and Cellular Cardiology</i> , <b>2019</b> , 130, 65-75	5.8	13
29	Phenotypic and molecular characterisation of type 3 von Willebrand disease in a cohort of Indian patients. <i>Thrombosis and Haemostasis</i> , <b>2013</b> , 109, 652-60	7	13
28	Cardiomyocyte-specific deletion of GSK-3 $\beta$ leads to cardiac dysfunction in a diet induced obesity model. <i>International Journal of Cardiology</i> , <b>2018</b> , 259, 145-152	3.2	12

27	Carrier detection in Glanzmann thrombasthenia: comparison of flow cytometry and Western blot with respect to DNA mutation. <i>American Journal of Clinical Pathology</i> , <b>2008</b> , 130, 93-8	1.9	12
26	Chronic Neuregulin-1 Treatment Mitigates the Progression of Postmyocardial Infarction Heart Failure in the Setting of Type 1 Diabetes Mellitus by Suppressing Myocardial Apoptosis, Fibrosis, and Key Oxidant-Producing Enzymes. <i>Journal of Cardiac Failure</i> , <b>2017</b> , 23, 887-899	3.3	11
25	Modulation of clinical phenotype of Glanzmann's thrombasthenia by thrombogenic mutations. <i>Clinica Chimica Acta</i> , <b>2009</b> , 403, 156-8	6.2	10
24	Glanzmann's thrombasthenia in North Indians: sub classification and carrier detection by flow cytometry. <i>Platelets</i> , <b>2009</b> , 20, 12-5	3.6	10
23	Evidence for non-HFE linked hemochromatosis in Asian Indians. <i>Indian Journal of Medical Sciences</i> , <b>2006</b> , 60, 491-5		10
22	Impact of 789Ala/Ala genotype on quantitative type of von Willebrand disease. <i>Annals of Hematology</i> , <b>2009</b> , 88, 479-83	3	8
21	Role of SARS-CoV-2 -induced cytokines and growth factors in coagulopathy and thromboembolism. <i>Cytokine and Growth Factor Reviews</i> , <b>2021</b> ,	17.9	7
20	Impact of thrombogenic mutations on clinical phenotypes of von Willebrand disease. <i>Clinical and Applied Thrombosis/Hemostasis</i> , <b>2010</b> , 16, 281-7	3.3	5
19	Acquired Glanzmann's thrombasthenia associated with Hairy cell leukaemia. <i>European Journal of Clinical Investigation</i> , <b>2009</b> , 39, 1110-1	4.6	4
18	Nicotinamide riboside kinase-2 alleviates ischemia-induced heart failure through P38 signaling. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , <b>2020</b> , 1866, 165609	6.9	4
17	Role of RFLP using TspRI for carrier detection in Glanzmann's thrombasthenia: a report on two families. <i>International Journal of Laboratory Hematology</i> , <b>2010</b> , 32, e158-62	2.5	3
16	Functional characterization of antibodies against heparin-platelet factor 4 complex in heparin-induced thrombocytopenia patients in Asian-Indians: relevance to inflammatory markers. <i>Blood Coagulation and Fibrinolysis</i> , <b>2005</b> , 16, 487-90	1	3
15	Response by Zhou et al to Letter Regarding Article, "Loss of Adult Cardiac Myocyte GSK-3 Leads to Mitotic Catastrophe Resulting in Fatal Dilated Cardiomyopathy". <i>Circulation Research</i> , <b>2016</b> , 119, e29-e30	15.7	3
14	Characterization of VWF gene conversions causing von Willebrand disease. <i>British Journal of Haematology</i> , <b>2019</b> , 184, 817-825	4.5	3
13	SARS-CoV-2 infection induces soluble platelet activation markers and PAI-1 in the early moderate stage of COVID-19. <i>International Journal of Laboratory Hematology</i> , <b>2022</b> ,	2.5	3
12	Coinheritance of severe von Willebrand disease with Glanzmann thrombasthenia. <i>Clinical and Applied Thrombosis/Hemostasis</i> , <b>2010</b> , 16, 529-32	3.3	2
11	Abstract P357: Induction Of Soluble P-selectin And CD40 Ligand And, FXIII Deficiency Promote Aberrant Coagulation And Thromboembolism In Severe COVID-19. <i>Circulation Research</i> , <b>2021</b> , 129,	15.7	2
10	Induction of soluble platelet activation markers and FXIII deficiency promote COVID-19 severity		2

9	Germline de novo mutations and linkage markers vs. DNA sequencing for carrier detection in von Willebrand disease. <i>Haemophilia</i> , <b>2014</b> , 20, e311-7	3.3	1
8	Gene tracking in a family of novel identical twins affected by severe type-III von Willebrand Disease (vWD). <i>Thrombosis Research</i> , <b>2007</b> , 120, 459-62	8.2	1
7	Use of CSGE, TspRI- RFLP and Western Blot in Carrier Detection in an Indian Family with Type I Glanzmann Thrombasthenia.. <i>Blood</i> , <b>2006</b> , 108, 3975-3975	2.2	1
6	Lipocalin-2, S100A8/A9, and cystatin C: Potential predictive biomarkers of cardiovascular complications in COVID-19.. <i>Experimental Biology and Medicine</i> , <b>2022</b> , 15353702221091990	3.7	1
5	Comorbidities and clinical complications associated with SARS-CoV-2 infection: an overview.. <i>Clinical and Experimental Medicine</i> , <b>2022</b> , 1	4.9	0
4	Mutation Screening of GPIIb and GPIIIa Exons by Conformation Sensitive Gel Electrophoresis.. <i>Blood</i> , <b>2007</b> , 110, 3218-3218	2.2	
3	Glanzmann's Thrombasthenia Patients with No Mutations in Both the ITGA2B and ITGB3 Genes as Identified by Conformation Sensitive Gel Electrophoresis (CSGE). <i>Blood</i> , <b>2008</b> , 112, 1236-1236	2.2	
2	STIM1 Deficiency Results In Impaired Platelet Procoagulant Activity and Protection From Arterial Thrombosis. <i>Blood</i> , <b>2010</b> , 116, 485-485	2.2	
1	Critical Role of CalDAG-GEFI In FCRIIa-Dependent Platelet Activation and Thrombosis. <i>Blood</i> , <b>2010</b> , 116, 3196-3196	2.2	